Details of the Drug Reposition

General Information of This Drug (ID: DM3I5NU)

Drug Name
TPI 287   DM3I5NU
Synonyms
FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioma DIS5RPEH 2A00.0 Phase 2 [1]
------------------------------------------------------------------------------------
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Brain metastases DISHVCOZ 2D50 Phase 1 [2]
Progressive supranuclear palsy DISO5KRQ 8A00.10 Phase 1 [1]
Alzheimer disease DISF8S70 8A20 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)